ArticleClinical case reports2025
Complete Resolution of Cutaneous Leishmaniasis With a Novel Topical Combination Therapy: A Case Series.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complete Resolution of Cutaneous Leishmaniasis With a Novel Topical Combination Therapy: A Case Series.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous leishmaniasis (CL) remains a therapeutic challenge in endemic regions, with 600,000-1 million new cases annually facing limited treatment options. We present a case series evaluating an innovative topical combination therapy for acute-phase CL in Shiraz, Iran. Three treatment-naïve patients (45-year-old female with forearm lesions, 18-year-old male with foot involvement, and 52-year-old female with hand lesions) received daily applications of a novel solution containing ciprofloxacin, ketoconazole, and metronidazole for 30 days, followed by alpha hydroxy acid for scar rehabilitation. Remarkably, all patients demonstrated complete lesion resolution and significant cosmetic improvement without treatment-related adverse events. This well-tolerated regimen offers several advantages over conventional systemic antimonials, including reduced toxicity, improved accessibility, and simplified administration. Our findings support the growing body of evidence for topical CL treatments, offering a potentially safer, more accessible option that warrants further clinical investigation in endemic regions. This study highlights the importance of developing targeted therapies that consider both clinical efficacy and practical implementation challenges in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.